As of 2025-03-22, the Relative Valuation of Y-mAbs Therapeutics, Inc (YMAB) is (25.00) USD. This relative valuation is based on P/E multiples. With the latest stock price at 5.00 USD, the upside of Y-mAbs Therapeutics, Inc based on Relative Valuation is -599.9%.
The range of the Relative Valuation is (20.61) - (32.21) USD.
Note: valuation result may not be accurate due to the low predictability of business.
| Range | Selected | |
| Trailing P/E multiples | 31.4x - 49.1x | 41.5x |
| Forward P/E multiples | 26.9x - 49.9x | 34.7x |
| Fair Price | (20.61) - (32.21) | (25.00) |
| Upside | -512.3% - -744.2% | -599.9% |
| Date | P/E |